Laura A Adang1, Francesco Gavazzi2, Abbas F Jawad3, Stacy V Cusack4, Kimberly Kopin5, Kyle Peer2, Constance Besnier2, Micaela De Simone6, Valentina De Giorgis7, Simona Orcesi7, Elisa Fazzi6, Jessica Galli6, Justine Shults8, Adeline Vanderver2. 1. Division of Neurology, Children's Hospital of Philadelphia, United States. Electronic address: adangl@email.chop.edu. 2. Division of Neurology, Children's Hospital of Philadelphia, United States. 3. Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, United States. 4. Division of Occupational Therapy, Children's Hospital of Philadelphia, United States. 5. Division of Physical Therapy, Children's Hospital of Philadelphia, United States. 6. Child Neurology and Psychiatry Unit, ASST Spedali Civili of Brescia, Italy. 7. Department of Child Neurology and Psychiatry, IRCCS Mondino Foundation, Pavia, Italy. 8. Department of Biostatistics, Perelman School of Medicine at University of Pennsylvania, United States.
Abstract
BACKGROUND AND PURPOSE: Aicardi Goutières Syndrome (AGS) is a severe, autoinflammatory leukodystrophy characterized by global neurologic dysfunction. Our goal was to create an easy-to-apply scale relevant to the unique developmental challenges associated with AGS. METHODS: All individuals were recruited through our natural history study. Individuals were classified by AGS severity as mild, moderate, or severe, and clinical encounters were assigned a composite score for neurologic function calculated from the sum of three functional classification scales. Through expert consensus, we identified 11 key items to reflect the severity of AGS across gross motor, fine motor, and cognitive skills to create the AGS Scale. There was strong interrater reliability. The AGS scale was applied across available medical records to evaluate neurologic function over time. The AGS scale was compared to performance on a standard measure of gross motor function (Gross Motor Function Measure-88, GMFM-88) and a putative diagnostic biomarker of disease, the interferon signaling gene expression score (ISG). RESULTS: The AGS scale score correlated with severity classifications and the composite neurologic function scores. When retrospectively applied across our natural history study, the majority of individuals demonstrated an initial decline in function followed by stable scores. Within the first 6 months of disease, the AGS score was the most dynamic. The AGS scale correlated with performance by the GMFM-88, but did not correlate with ISG levels. CONCLUSIONS: This study demonstrates the utility of the AGS scale as a multimodal tool for the assessment of neurologic function in AGS. The AGS scale correlates with clinical severity and with a more labor-intensive tool, GMFM-88. This study underscores the limitations of the ISG score as a marker of disease severity. With the AGS scale, we found that AGS neurologic severity is the most dynamic early in disease. This novel AGS scale is a promising tool to longitudinally follow neurologic function in this unique population.
BACKGROUND AND PURPOSE: Aicardi Goutières Syndrome (AGS) is a severe, autoinflammatory leukodystrophy characterized by global neurologic dysfunction. Our goal was to create an easy-to-apply scale relevant to the unique developmental challenges associated with AGS. METHODS: All individuals were recruited through our natural history study. Individuals were classified by AGS severity as mild, moderate, or severe, and clinical encounters were assigned a composite score for neurologic function calculated from the sum of three functional classification scales. Through expert consensus, we identified 11 key items to reflect the severity of AGS across gross motor, fine motor, and cognitive skills to create the AGS Scale. There was strong interrater reliability. The AGS scale was applied across available medical records to evaluate neurologic function over time. The AGS scale was compared to performance on a standard measure of gross motor function (Gross Motor Function Measure-88, GMFM-88) and a putative diagnostic biomarker of disease, the interferon signaling gene expression score (ISG). RESULTS: The AGS scale score correlated with severity classifications and the composite neurologic function scores. When retrospectively applied across our natural history study, the majority of individuals demonstrated an initial decline in function followed by stable scores. Within the first 6 months of disease, the AGS score was the most dynamic. The AGS scale correlated with performance by the GMFM-88, but did not correlate with ISG levels. CONCLUSIONS: This study demonstrates the utility of the AGS scale as a multimodal tool for the assessment of neurologic function in AGS. The AGS scale correlates with clinical severity and with a more labor-intensive tool, GMFM-88. This study underscores the limitations of the ISG score as a marker of disease severity. With the AGS scale, we found that AGS neurologic severity is the most dynamic early in disease. This novel AGS scale is a promising tool to longitudinally follow neurologic function in this unique population.
Authors: Laura A Adang; David B Frank; Ahmed Gilani; Asako Takanohashi; Nicole Ulrick; Abigail Collins; Zachary Cross; Csaba Galambos; Guy Helman; Usama Kanaan; Stephanie Keller; Dawn Simon; Omar Sherbini; Brian D Hanna; Adeline L Vanderver Journal: Mol Genet Metab Date: 2018-09-07 Impact factor: 4.797
Authors: Ann-Christin Eliasson; Lena Krumlinde-Sundholm; Birgit Rösblad; Eva Beckung; Marianne Arner; Ann-Marie Ohrvall; Peter Rosenbaum Journal: Dev Med Child Neurol Date: 2006-07 Impact factor: 5.449
Authors: Richard S Finkel; Eugenio Mercuri; Basil T Darras; Anne M Connolly; Nancy L Kuntz; Janbernd Kirschner; Claudia A Chiriboga; Kayoko Saito; Laurent Servais; Eduardo Tizzano; Haluk Topaloglu; Már Tulinius; Jacqueline Montes; Allan M Glanzman; Kathie Bishop; Z John Zhong; Sarah Gheuens; C Frank Bennett; Eugene Schneider; Wildon Farwell; Darryl C De Vivo Journal: N Engl J Med Date: 2017-11-02 Impact factor: 91.245
Authors: Robert J Palisano; Lisa Avery; Jan Willem Gorter; Barbara Galuppi; Sarah Westcott McCoy Journal: Dev Med Child Neurol Date: 2018-05-04 Impact factor: 5.449
Authors: Gillian I Rice; Jacquelyn Bond; Aruna Asipu; Rebecca L Brunette; Iain W Manfield; Ian M Carr; Jonathan C Fuller; Richard M Jackson; Teresa Lamb; Tracy A Briggs; Manir Ali; Hannah Gornall; Lydia R Couthard; Alec Aeby; Simon P Attard-Montalto; Enrico Bertini; Christine Bodemer; Knut Brockmann; Louise A Brueton; Peter C Corry; Isabelle Desguerre; Elisa Fazzi; Angels Garcia Cazorla; Blanca Gener; Ben C J Hamel; Arvid Heiberg; Matthew Hunter; Marjo S van der Knaap; Ram Kumar; Lieven Lagae; Pierre G Landrieu; Charles M Lourenco; Daphna Marom; Michael F McDermott; William van der Merwe; Simona Orcesi; Julie S Prendiville; Magnhild Rasmussen; Stavit A Shalev; Doriette M Soler; Marwan Shinawi; Ronen Spiegel; Tiong Y Tan; Adeline Vanderver; Emma L Wakeling; Evangeline Wassmer; Elizabeth Whittaker; Pierre Lebon; Daniel B Stetson; David T Bonthron; Yanick J Crow Journal: Nat Genet Date: 2009-06-14 Impact factor: 38.330
Authors: Yanick J Crow; Diana S Chase; Johanna Lowenstein Schmidt; Marcin Szynkiewicz; Gabriella M A Forte; Hannah L Gornall; Anthony Oojageer; Beverley Anderson; Amy Pizzino; Guy Helman; Mohamed S Abdel-Hamid; Ghada M Abdel-Salam; Sam Ackroyd; Alec Aeby; Guillermo Agosta; Catherine Albin; Stavit Allon-Shalev; Montse Arellano; Giada Ariaudo; Vijay Aswani; Riyana Babul-Hirji; Eileen M Baildam; Nadia Bahi-Buisson; Kathryn M Bailey; Christine Barnerias; Magalie Barth; Roberta Battini; Michael W Beresford; Geneviève Bernard; Marika Bianchi; Thierry Billette de Villemeur; Edward M Blair; Miriam Bloom; Alberto B Burlina; Maria Luisa Carpanelli; Daniel R Carvalho; Manuel Castro-Gago; Anna Cavallini; Cristina Cereda; Kate E Chandler; David A Chitayat; Abigail E Collins; Concepcion Sierra Corcoles; Nuno J V Cordeiro; Giovanni Crichiutti; Lyvia Dabydeen; Russell C Dale; Stefano D'Arrigo; Christian G E L De Goede; Corinne De Laet; Liesbeth M H De Waele; Ines Denzler; Isabelle Desguerre; Koenraad Devriendt; Maja Di Rocco; Michael C Fahey; Elisa Fazzi; Colin D Ferrie; António Figueiredo; Blanca Gener; Cyril Goizet; Nirmala R Gowrinathan; Kalpana Gowrishankar; Donncha Hanrahan; Bertrand Isidor; Bülent Kara; Nasaim Khan; Mary D King; Edwin P Kirk; Ram Kumar; Lieven Lagae; Pierre Landrieu; Heinz Lauffer; Vincent Laugel; Roberta La Piana; Ming J Lim; Jean-Pierre S-M Lin; Tarja Linnankivi; Mark T Mackay; Daphna R Marom; Charles Marques Lourenço; Shane A McKee; Isabella Moroni; Jenny E V Morton; Marie-Laure Moutard; Kevin Murray; Rima Nabbout; Sheela Nampoothiri; Noemi Nunez-Enamorado; Patrick J Oades; Ivana Olivieri; John R Ostergaard; Belén Pérez-Dueñas; Julie S Prendiville; Venkateswaran Ramesh; Magnhild Rasmussen; Luc Régal; Federica Ricci; Marlène Rio; Diana Rodriguez; Agathe Roubertie; Elisabetta Salvatici; Karin A Segers; Gyanranjan P Sinha; Doriette Soler; Ronen Spiegel; Tommy I Stödberg; Rachel Straussberg; Kathryn J Swoboda; Mohnish Suri; Uta Tacke; Tiong Y Tan; Johann te Water Naude; Keng Wee Teik; Maya Mary Thomas; Marianne Till; Davide Tonduti; Enza Maria Valente; Rudy Noel Van Coster; Marjo S van der Knaap; Grace Vassallo; Raymon Vijzelaar; Julie Vogt; Geoffrey B Wallace; Evangeline Wassmer; Hannah J Webb; William P Whitehouse; Robyn N Whitney; Maha S Zaki; Sameer M Zuberi; John H Livingston; Flore Rozenberg; Pierre Lebon; Adeline Vanderver; Simona Orcesi; Gillian I Rice Journal: Am J Med Genet A Date: 2015-01-16 Impact factor: 2.802
Authors: Kader Cetin Gedik; Lovro Lamot; Micol Romano; Erkan Demirkaya; David Piskin; Sofia Torreggiani; Laura A Adang; Thais Armangue; Kathe Barchus; Devon R Cordova; Yanick J Crow; Russell C Dale; Karen L Durrant; Despina Eleftheriou; Elisa M Fazzi; Marco Gattorno; Francesco Gavazzi; Eric P Hanson; Min Ae Lee-Kirsch; Gina A Montealegre Sanchez; Bénédicte Neven; Simona Orcesi; Seza Ozen; M Cecilia Poli; Elliot Schumacher; Davide Tonduti; Katsiaryna Uss; Daniel Aletaha; Brian M Feldman; Adeline Vanderver; Paul A Brogan; Raphaela Goldbach-Mansky Journal: Ann Rheum Dis Date: 2022-01-27 Impact factor: 27.973
Authors: Francesco Gavazzi; Laura Adang; Amy Waldman; Amanda K Jan; Geraldine Liu; Scott A Lorch; Sara B DeMauro; Justine Shults; Samuel R Pierce; Elizabeth Ballance; Tracy Kornafel; Ann Harrington; Allan M Glanzman; Adeline Vanderver Journal: Pediatr Neurol Date: 2021-09-24 Impact factor: 4.210